Our Pricing

Understanding Wegovy UK Prices Across All Doses

Published on: June 03, 2026

Searching for transparent wegovy uk prices all doses before committing to treatment? At Cured Pharmacy, we display upfront pricing from £79.00 for UK-licensed Wegovy (semaglutide) injections, with all doses available subject to clinical assessment by our UK-registered prescribers.

How Wegovy Semaglutide Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the action of glucagon-like peptide-1, a hormone that regulates appetite and food intake by acting on receptors in the brain.

In the landmark STEP 1 trial, participants using Wegovy alongside lifestyle interventions achieved an average weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing hunger signals, and increasing feelings of fullness after meals, making it easier to maintain a reduced-calorie diet.

Unlike older weight loss medications that work solely in the digestive system, semaglutide's central nervous system action addresses the neurological components of appetite regulation [2]. This dual mechanism explains why clinical trial participants reported sustained appetite reduction throughout the treatment period, rather than developing tolerance as seen with some earlier medications.

Wegovy Dosing Schedule and UK Pricing Structure

At Cured Pharmacy, our transparent pricing structure reflects the actual dose you're prescribed following your clinical assessment. The starting price from £79.00 applies to initial lower-dose pens, with pricing adjusted as you progress through the titration schedule to higher maintenance doses.

Unlike some providers who quote headline prices for unavailable starter doses, we maintain stock across the full dose range and display real-time availability before your consultation begins. All Wegovy pens dispensed through our pharmacy are sourced directly from UK-licensed wholesalers and carry full MHRA product authorisation.

Understanding the Dose Escalation Protocol

Wegovy treatment follows a carefully designed dose escalation schedule to minimise gastrointestinal side effects whilst optimising weight loss outcomes. Patients typically begin with 0.25mg weekly for four weeks, then increase gradually through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [3].

This gradual titration allows your body to adapt to the medication's effects on gastric motility and appetite signalling. UK prescribers may adjust the escalation timeline based on individual tolerance, and some patients may remain on lower doses if they achieve satisfactory results or experience persistent side effects at higher strengths.

Comparing Wegovy to Alternative Weight Loss Treatments

The UK weight loss treatment landscape now includes several prescription options, each with distinct mechanisms and clinical profiles. Whilst Wegovy remains the most extensively studied GLP-1 treatment for weight management, newer dual-agonist medications and established oral treatments offer alternatives depending on individual circumstances and preferences.

Mounjaro (tirzepatide) represents the latest advancement, combining GLP-1 and GIP receptor agonism to produce enhanced metabolic effects. Clinical trials comparing tirzepatide to semaglutide showed superior weight loss outcomes, with SURPASS-2 demonstrating up to 22.5% average body weight reduction at the highest dose versus 15% with semaglutide [4]. However, Wegovy's longer track record and extensive real-world safety data make it a trusted first-line option for many UK prescribers.

For patients who prefer non-injectable options or have lower BMI thresholds, oral medications like Orlistat work through fat absorption inhibition rather than appetite regulation. These treatments typically produce more modest weight loss averaging 5-10% but suit individuals uncomfortable with self-injection or those seeking to complement dietary changes with digestive-level intervention [5].

Clinical Eligibility Criteria for Wegovy in the UK

Patients are expected to combine Wegovy with a reduced-calorie diet and increased physical activity, as clinical trials demonstrating efficacy included lifestyle intervention components [1]. UK prescribers typically review progress at 12-16 weeks, discontinuing treatment if patients haven't achieved at least 5% weight loss, in line with NICE recommendations for GLP-1 therapies.

Certain medical conditions preclude Wegovy use, including severe gastrointestinal disease, diabetic retinopathy complications, and pregnancy or breastfeeding. Our clinical team conducts thorough screening to ensure patient safety, and Superintendent Pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing decisions to maintain the highest standards of pharmaceutical care.

BMI Requirements and Medical Assessment

NICE guidance and MHRA licensing specify that Wegovy is indicated for adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [6].

During your online consultation at Cured Pharmacy, our UK-registered prescribers assess your current weight, height, medical history, and any contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The assessment also reviews current medications to identify potential interactions and ensure semaglutide is clinically appropriate for your circumstances.

Managing Side Effects and Treatment Expectations

The most commonly reported side effects of Wegovy involve the gastrointestinal system, with nausea, diarrhoea, vomiting, and constipation affecting more than 10% of trial participants [3]. These effects typically emerge during dose escalation and diminish as treatment continues, though approximately 5-7% of patients discontinue due to persistent gastrointestinal intolerance.

To minimise side effects, UK prescribers recommend eating smaller, more frequent meals, avoiding high-fat foods that slow gastric emptying further, and staying well-hydrated throughout treatment. Injecting Wegovy at consistent times and rotating injection sites between the abdomen, thigh, and upper arm can also improve tolerance and absorption consistency.

Realistic weight loss expectations are essential for treatment satisfaction. Whilst clinical trials showed average reductions approaching 15%, individual responses vary considerably based on baseline metabolic health, adherence to lifestyle modifications, and genetic factors affecting GLP-1 receptor sensitivity [2]. Most patients notice appetite suppression within the first few weeks, with measurable weight loss typically evident by week 8-12 of treatment.

Why Choose Cured Pharmacy for Wegovy UK Prescriptions

We guarantee 100% discreet packaging with no external branding or medication details visible on parcels, and all Wegovy pens are shipped in temperature-controlled packaging to maintain the cold chain required for semaglutide stability. Our pharmacy dispenses only genuine UK-licensed medications sourced through MHRA-approved wholesalers, never grey-market imports or compounded alternatives.

Your online consultation takes under three minutes to complete and includes comprehensive questions about your medical history, current medications, and weight loss goals. UK prescribers typically review submissions within 24 hours, and approved prescriptions are dispensed and dispatched the same working day for next-day delivery across most UK postcodes.

Transparent Pricing and Clinical Excellence

At Cured Pharmacy, we display exact pricing before your consultation begins, eliminating the frustration of discovering costs only after completing lengthy assessments. Our wegovy uk prices all doses structure reflects genuine UK pharmacy costs without hidden consultation fees or subscription lock-ins that some providers use to inflate lifetime treatment expenses.

Every prescription is reviewed by UK-registered clinicians operating under General Pharmaceutical Council oversight (GPhC 9012511), ensuring you receive the same standard of care as traditional high-street pharmacies whilst benefiting from the convenience and discretion of online service. Our clinical team includes experienced prescribers who specialise in weight management and metabolic health.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Yanovski, S. Z., & Yanovski, J. A. (2014). Long-term Drug Treatment for Obesity: A Systematic and Clinical Review. JAMA, 311(1), 74–86. https://doi.org/10.1001/jama.2013.281361 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.